文献速递中枢神经肿瘤放疗放疗物理与技术

个体化超分割立体定向自适应放疗(PULSAR)联合中枢神经系统活性药物治疗脑转移的探索性评估

Exploratory Evaluation of Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) With Central Nervous System-Active Drugs in Brain Metastases Treatment.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-11-17

该回顾性研究评估了2018至2024年采用伽玛刀PULSAR治疗的109个脑转移病灶,中位随访1.72年,2年局部失败率为8.9%,同步使用中枢神经系统活性药物者2年局部失败率为5.5%,2年3级及以上毒性发生率为8.7%,同步用药未增加毒性。作者认为PULSAR联合中枢神经系统活性药物对较大脑转移似可提供良好局部控制且毒性有限,但结论需进一步前瞻性研究验证。

要点

  • PULSAR治疗脑转移的2年局部失败率为8.9%,同步使用中枢神经系统活性药物者为5.5%。
  • 直径大于2 cm的脑转移2年局部失败率为9.4%,联合PULSAR与中枢神经系统活性药物者在2.5年时未观察到局部失败。
  • PULSAR的2年3级及以上毒性发生率为8.7%,同步使用中枢神经系统活性药物未增加毒性。

核心结论

  • PULSAR联合中枢神经系统活性药物似乎对较大脑转移提供良好的局部控制且毒性有限。
  • 这些有希望的结果值得进一步前瞻性研究以验证发现并可能建立新的治疗方案。

研究设计与样本

  • 本研究为回顾性评估,纳入2018年至2024年使用伽玛刀接受PULSAR治疗的患者。
  • 分析纳入109个接受PULSAR治疗的病灶,患者以肺癌和乳腺癌为主。
  • 采用考虑死亡为竞争风险的累积 incidence 分析评估局部失败和毒性,采用Kaplan-Meier生存分析评估总生存。

主要发现

  • 中位随访时间为1.72,中位总生存未达到。
  • 1年和2年局部失败率分别为5%和8.9%,同步使用中枢神经系统活性药物者分别为3.4%和5.5%。
  • 直径大于2 cm的脑转移2年局部失败率为9.4%。
  • 直径大于2 cm的脑转移接受PULSAR联合中枢神经系统活性药物治疗者在2.5年时未观察到局部失败。
  • 单因素分析提示中枢神经系统活性药物和放射敏感性组织学与局部失败率降低相关。

临床怎么用

  • 本研究中心倡导使用PULSAR,以高剂量脉冲、延长间隔方式给予放疗,便于治疗自适应和同期系统治疗整合。
  • 作者认为PULSAR联合中枢神经系统活性药物似乎对较大脑转移提供良好局部控制且毒性有限,并建议进一步前瞻性研究验证。

局限性

  • 本研究为回顾性评估。
  • 作者指出这些有希望的结果值得进一步前瞻性研究以验证发现并可能建立新的治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Brain metastases (BMs) affect an increasing number of cancer patients and are typically managed with stereotactic radiosurgery (SRS). Our institution advocates the use of Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR), where radiation is delivered in high-dose pulses at extended intervals allowing for treatment adaptation and easy concurrent systemic therapy integration. We explore the integration of PULSAR with central nervous system (CNS)-active drugs (CNS-aDs). METHODS AND MATERIALS: This study involved a retrospective evaluation of patients treated with PULSAR using Gamma Knife from 2018 to 2024. We collected demographic, clinical, and specific treatment details, as well as outcomes such as local failure (LF) and toxicity rates. Cumulative incidence analysis for LF and toxicity, considering death a competing risk, and Kaplan-Meier survival analysis for overall survival (OS) were conducted. RESULTS: Analysis included 109 lesions treated with PULSAR, predominantly in patients with lung and breast cancer. The median follow-up was 1.72. The median OS was not reached. The 1- and 2-year LF rates were 5% and 8.9%, respectively, and 3.4% and 5.5% with concurrent CNS-aDs (cCNS-aDs). BMs >2 cm had LF rates of 9.4% at 2 years. No LFs were observed in BMs >2 cm treated with the combined PULSAR+CNS-aDs approach at 2.5 years. Univariate analysis indicated CNS-aD and radioresponsive histologies were associated with decreased LF rates. The 2-year grade 3+ toxicity rate for PULSAR was 8.7%, with no increase in toxicity with cCNS-aDs. CONCLUSIONS: The integration of PULSAR with CNS-aDs appears to offer excellent local control for larger BMs with limited toxicity. These promising results merit further prospective investigation to validate the findings and potentially establish new treatment protocols.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dohopolski M, Schmitt LG, Anand S, et al. Exploratory Evaluation of Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) With Central Nervous System-Active Drugs in Brain Metastases Treatment. Int J Radiat Oncol Biol Phys. 2024. PMID: 39557308. doi:10.1016/j.ijrobp.2024.11.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。